Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, ...

A modified herpes virus boosted immune T cell infiltration in glioblastoma tumors and was associated with improved survival.

Phase 1 clinical trials evaluate the safety and dosage of proposed new treatments. Further research is needed to test the oncolytic virus therapy’s effectiveness and side effects. Work also continues ...

Glioblastoma is the most aggressive and deadliest form of brain cancer. Most patients survive only about a year after diagnosis, and just 5% make it to five years. Dr. Minesh P. Mehta is leading the ...

Researchers in China have developed magnetically controlled microrobots made from diatoms for the treatment of glioblastoma using photodynamic therapy. These microrobots exhibit excellent magnetic ...

The MarketWatch News Department was not involved in the creation of this content. -- Primary endpoint of QUILT-3.078 is overall survival; median overall survival has not yet been reached, with 19 of ...

Akeso (SEHK:9926) reported long term survival data from a Phase II study of cadonilimab in advanced cervical cancer, highlighting durable benefits in a setting with limited treatment options. The ...

Researchers from the University of Texas Health Science Center at San Antonio have developed a drug that more than doubled median survival time and progression-free time for patients with glioblastoma ...

An investigational drug for glioblastoma more than doubled survival and progression-free time compared to standard rates, reported a new study published in Nature Communications. Glioblastoma is the ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company developing cytokine and cellular immunotherapies designed to restore immune competence, today announced updated Phase 2 ...